<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060406</url>
  </required_header>
  <id_info>
    <org_study_id>LY06006/CT-CHN-302</org_study_id>
    <nct_id>NCT05060406</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be&#xD;
      conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal&#xD;
      women with osteoporosis at high risk for fracture, as well as an exploratory population&#xD;
      pharmacokinetic analysis of LY06006.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of LY06006 in the treatment of postmenopausal women with&#xD;
      osteoporosis at high risk for fracture.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate the safety of LY06006. To evaluate the immunogenicity of LY06006. Population&#xD;
      pharmacokinetic analysis of LY06006.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <description>Percent Change From Baseline in BMD at the Lumbar Spine at Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in total hip BMD</measure>
    <time_frame>Baseline,Month 6 and Month 12</time_frame>
    <description>Percent Changes in total hip BMD from baseline at 6 and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in femoral neck BMD</measure>
    <time_frame>Baseline,Month 6 and Month 12</time_frame>
    <description>Percent Changes in femoral neck BMD from baseline at 6 and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes in trochanteric BMD</measure>
    <time_frame>Baseline,Month 6 and Month 12</time_frame>
    <description>Percent Changes in trochanteric BMD from baseline at 6 and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline</measure>
    <time_frame>Baseline, Month 1, Month 6 and Month 12</time_frame>
    <description>Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1, Month 6, and Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline</measure>
    <time_frame>Baseline, Month 1, Month 6 and Month 12</time_frame>
    <description>Percent Change From Baseline in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline at Month 1, Month 6, and Month 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>LY06006 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection&#xD;
Interventions:&#xD;
Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection&#xD;
Interventions:&#xD;
Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY06006</intervention_name>
    <description>60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total</description>
    <arm_group_label>LY06006 60mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>recombinant human monoclonal anti-RANKL antibody injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal woman, ages ≥50 to ≤85 years.≥3 years postmenopausal, which can be≥3&#xD;
             years of spontaneous amenorrhea or ≥3 years post-surgical bilateral oophorectomy. If &lt;&#xD;
             60 years of age and had hysterectomy but ovarian retention, require follicle&#xD;
             stimulating hormone (FSH) levels ≥40U/L.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          2. Low BMD (BMD absolute value consistent with a T-score≤-2.5 and &gt;-4.0 at either the&#xD;
             lumbar spine or total hip). The BMD equivalents by T-score thresholds for each DXA&#xD;
             scanner manufacturer are provided below.&#xD;
&#xD;
          3. Have at least one of the following risk factors:&#xD;
&#xD;
               1. history of fragility fracture&#xD;
&#xD;
               2. parental history of hip fracture&#xD;
&#xD;
               3. low body weight (BMI≤19kg/m2)&#xD;
&#xD;
               4. elderly (age≥65y)&#xD;
&#xD;
               5. current smoker&#xD;
&#xD;
          4. Voluntarily signed written informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Bone/metabolic disease:&#xD;
&#xD;
               1. Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta,&#xD;
&#xD;
               2. Paget's disease&#xD;
&#xD;
               3. Cushing's disease&#xD;
&#xD;
               4. Hyperprolactinemia&#xD;
&#xD;
               5. Hypopituitarism&#xD;
&#xD;
               6. Acromegaly&#xD;
&#xD;
               7. Current hyperparathyroidism or hypoparathyroidism by medical record.&#xD;
&#xD;
               8. Current hyperthyroidism or hypothyroidism (allowed if having normal hormone level&#xD;
                  on thyroid hormone replacement therapy or 5.5μIU/mL&lt;thyroid-stimulating hormone&#xD;
                  (TSH) level≤10.0μIU/mL, but the serum thyroxine (T4) is within the normal range.&#xD;
&#xD;
               9. Malabsorption syndrome or any gastrointestinal disorders associated with&#xD;
                  malabsorption, for example Crohn's Disease and chronic pancreatitis.&#xD;
&#xD;
              10. Hypocalcemia or hypercalcemia, or serum albumin corrected blood calcium level is&#xD;
                  not within the normal range of the laboratory;&#xD;
&#xD;
              11. Vitamin D deficiency: 25 hydroxy vitamin D (25OHD) level &lt;20 ng/mL. (allowed&#xD;
                  200,000 units of vitamin D2 injection (trade name: Futai®) once during the&#xD;
                  screening period, and re-test the 25OHD level once. Those with 25OHD level ≥20&#xD;
                  ng/mL can be included&#xD;
&#xD;
              12. Others such as rheumatoid arthritis, gout, multiple myeloma and so on.&#xD;
&#xD;
          2. Subjects with a history of greater than 2 vertebral fractures.&#xD;
&#xD;
          3. Malignancy within the 5 years before enrollment (except fully resected cutaneous basal&#xD;
             cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ).&#xD;
&#xD;
          4. Severe renal disease, creatinine clearance &lt;30mL/min&#xD;
&#xD;
          5. Liver or biliary diseases:&#xD;
&#xD;
               1. Cirrhosis of the liver;&#xD;
&#xD;
               2. Biliary tract abnormalities (except asymptomatic gallstones);&#xD;
&#xD;
               3. Positive Hepatitis C virus (HCV) antibody;&#xD;
&#xD;
               4. Positive hepatitis B surface antigen (HBsAg) test with the peripheral blood&#xD;
                  hepatitis B virus deoxyribonucleic acid (HBV DNA) titer test ≥1×103 copies/mL (if&#xD;
                  positive HBsAg with the peripheral blood HBV DNA titer test &lt;1× 103 copies/mL,&#xD;
                  the subject is eligible for selection if the investigator believes that the&#xD;
                  subject is in a stable phase of chronic hepatitis B and will not increase the&#xD;
                  risk of the subject,;&#xD;
&#xD;
               5. Alkaline phosphatase &lt;lower limit of normal (LLN); alkaline phosphatase or total&#xD;
                  bilirubin ≥ 1.5 times the upper limit of normal (ULN); serum aspartate&#xD;
                  aminotransferase (AST) ≥ 2.0×ULN; serum alanine Acid aminotransferase (ALT)&#xD;
                  ≥2.0×ULN;&#xD;
&#xD;
          6. Oral/Dental Diseases&#xD;
&#xD;
               1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.&#xD;
&#xD;
               2. Active dental or jaw condition which requires oral surgery.&#xD;
&#xD;
               3. Planned invasive dental procedure.&#xD;
&#xD;
               4. Non-healed dental or oral surgery.&#xD;
&#xD;
          7. DXA measurements:&#xD;
&#xD;
               1. Less than two lumbar vertebrae evaluable for DXA measurements.&#xD;
&#xD;
               2. Height, weight, or girth that could preclude accurate DXA measurements.&#xD;
&#xD;
          8. Administration of the following medications:&#xD;
&#xD;
               1. RANKL inhibitor, fluoride or strontium salt or intravenous bisphosphonate within&#xD;
                  the past 5 years;&#xD;
&#xD;
               2. Oral bisphosphonates, allowed if patients had the following conditions :&#xD;
&#xD;
                    -  Cumulative use&gt; 3 months but &lt;3 years: ≥ 6 months before the last medication&#xD;
                       was taken from the screening visit;&#xD;
&#xD;
                    -  Cumulative use ≤3 months;&#xD;
&#xD;
               3. parathyroid hormone (PTH) or parathyroid hormone analogs (PTHa) within 6 weeks&#xD;
                  before screening, such as teriparatide; anabolic hormones or testosterone;&#xD;
                  glucocorticoids (equivalent to&gt; 5 mg/day strength Pine&gt; 10 days); systemic&#xD;
                  hormone replacement therapy; selective estrogen receptor modulators (SERMs), such&#xD;
                  as raloxifene; tibolone; calcitonin; active vitamin D and its analogs; other bone&#xD;
                  active drugs including anticonvulsants (except benzodiazepines) and heparin;&#xD;
                  long-term systemic use of ketoconazole, androgens, corticotropin, cinacalcet,&#xD;
                  aluminum, lithium, protease inhibitors, methotrexate, Gonadotropin releasing&#xD;
                  hormone agonist;&#xD;
&#xD;
          9. Positive human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
         10. Self-reported alcohol or drug abuse [defined as drinking an average of 14 units or&#xD;
             more of alcoholic beverages per week in the 3 months before screening (1 unit = 350 mL&#xD;
             of beer, or 45 mL of liquor, or 150 mL of wine)]&#xD;
&#xD;
         11. Known allergy to the treatment drugs used in the research protocol, including allergy&#xD;
             to the test drugs&#xD;
&#xD;
         12. Have received any other experimental drug treatment or prior participation in another&#xD;
             interventional clinical trial within 3 months before screening&#xD;
&#xD;
         13. Other severe acute or chronic diseases, psychiatric disorder or abnormal laboratory&#xD;
             tests, etc., in the opinion of the investigator, not suitable for participating in&#xD;
             this research.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal woman</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenlin Zhang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenlin Zhang, doctor</last_name>
    <phone>13621673716</phone>
    <email>zzl2002@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiemei Gu, doctor</last_name>
    <phone>13916925072</phone>
    <email>gujiemei81@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenlin Zhang, doctor</last_name>
      <phone>13621673716</phone>
      <email>zzl2002@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhenlin Zhang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiemei Gu, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

